From: Pathological evaluation of neoadjuvant chemotherapy in advanced gastric cancer
Pre-chemotherapy TNM stage | |||||
---|---|---|---|---|---|
GHR | n (%) | II | III | IV | p value* |
≥ 45% | 45 | 18 (40.0) | 25 (55.6) | 2 (4.4) | 0.124 |
< 45% | 42 | 23 (54.8) | 19 (45.2) | 0 (0.0) | |
≥ 50% | 44 | 17 (38.6) | 25 (56.8) | 2 (4.5) | 0.078 |
< 50% | 43 | 24 (55.8) | 19 (44.2) | 0 (0.0) | |
≥ 2/3 | 30 | 9 (30.0) | 20 (66.7) | 1 (3.3) | 0.021 |
< 2/3 | 57 | 32 (56.1) | 24 (42.1) | 1 (1.8) | |
≥ 90% | 15 | 4 (26.7) | 10 (66.7) | 1 (6.7) | 0.062 |
< 90% | 72 | 37 (51.4) | 34 (47.2) | 1 (1.4) |